Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

Lawmakers raised questions and concerns about the sale of genetic-testing company 23andMe during a hearing on Tuesday.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

23andMe declared bankruptcy in March and announced it would seek a buyer, while also saying that co-founder and CEO ... Regeneron said Monday that it will abide by 23andMe's privacy policies ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.